Mochida Pharmaceutical on March 26 submitted an application in Japan seeking regulatory approval for its biosimilar version of Chugai Pharmaceutical’s anti-IL-6 receptor antibody Actemra (tocilizumab). Mochida and its commercial partner Ayumi Pharmaceutical announced the submission the same day. The biosimilar…
To read the full story
Related Article
- Mochida to File Actemra Biosimilar in Japan
January 16, 2025
BUSINESS
- Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026
- Nitrosamine Detected in Viatris’ Jzoloft OD Tablets
June 4, 2026
- RaQualia, RIKEN Team Up on Drug Discovery Technologies
June 4, 2026
- AbbVie Japan Says Sales-Doubling Plan on Track as Revenue Climbs 13.5%
June 3, 2026
- FunPep, Crafton Join Forces on Therapeutic mRNA Vaccines
June 3, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





